亲缘单倍体异基因造血干细胞移植联合第三方脐带血输注治疗高危淋巴细胞肿瘤效果分析  

Efficacy analysis of haploidentical allogeneic hematopoietic stem cell transplantation combined with third-party umbilical cord blood infusion in treatment of high-risk lymphoblastic malignancies

作　　者：施汪添翼 杨隽 蔡宇 万理萍[2] 牛家华[2] 王椿[2] 姜杰玲[2] Shi Wangtianyi;Yang Jun;Cai Yu;Wan Liping;Niu Jiahua;Wang Chun;Jiang Jieling(Department of Oncology,Suzhou Ninth People's Hospital,Suzhou 215200,China;Department of Hematology,Shanghai General Hospital,Shanghai 200080,China)

机构地区：[1]苏州市第九人民医院肿瘤科,215200 [2]上海交通大学附属上海市第一人民医院血液科,200080

出　　处：《白血病．淋巴瘤》2019年第6期333-339,共7页Journal of Leukemia & Lymphoma

摘　　要：目的评价亲缘单倍体异基因造血干细胞移植(Haplo-HSCT)联合第三方脐带血输注治疗高危淋巴细胞肿瘤的效果.方法回顾性分析上海市第一人民医院2012年4月至2015年4月20例确诊高危淋巴细胞恶性肿瘤并接受Haplo-HSCT联合脐带血输注治疗患者的资料,与同期匹配资料接受非血缘异基因造血干细胞移植(MUD-HSCT)的15例患者以及接受同胞全相合异基因造血干细胞移植(MSD-HSCT)的14例患者资料进行对比,评价Haplo-HSCT联合脐带血输注治疗高危淋巴细胞肿瘤的效果.预处理方案以替尼泊苷、环磷酰胺、全身照射为主,移植物抗宿主病(GVHD)预防方案包括环孢素A联合短程甲氨蝶呤,所有Haplo-HSCT联合脐带血输注以及MUD-HSCT患者加用抗胸腺细胞球蛋白(ATG).结果移植后MUD-HSCT组和MSD-HSCT组各有1例患者21d内死亡,不能评价,其余患者成功植入.Haplo-HSCT+脐带血组、MUD-HSCT组和MSD-HSCT组中性粒细胞中位植入时间分别为13d(10~18d)、12d(9~16d)和12d(9~14d);血小板中位植入时间分别为11d(9~18d)、12d(10~23d)和12d(9~14d).Haplo-HSCT+脐带血组、MUD-HSCT组和MSD-HSCT组100d发生Ⅱ~Ⅳ级急性GVHD分别有10、3、3例,2年发生慢性GVHD分别有6、4、3例;2年累积复发率分别为40.6%、66.2%和26.7%,预计2年总生存(OS)率分别为37.9%、42.9%和55.4%,以上各组数据比较差异均无统计学意义(均P>0.05).结论Haplo-HSCT联合脐带血输注治疗高危淋巴细胞肿瘤与MUD-HSCT或MSD-HSCT疗效类似.在缺乏匹配供者的情况下,可推荐其用于高危淋巴细胞肿瘤的治疗.Objective To evaluate the efficacy of haploidentical allogeneic hematopoietic stem cell transplantation (Haplo-HSCT) combined with third-party umbilical cord blood (UCB) infusion in treatment of high-risk lymphoblastic malignancies. Methods The clinical data of 20 patients with high-risk lymphoblastic malignancies who received Haplo-HSCT from April 2012 to April 2015 in Shanghai General Hospital were retrospectively analyzed, which were compared with the data from 15 patients who underwent matched unrelated donor HSCT (MUD-HSCT) or 14 matched sibling donor HSCT (MSD-HSCT) during the same period. The efficacy of Haplo-HSCT combined with UCB infusion in treatment of high-risk lymphoblastic malignancies was evaluated. The preparative regimen mainly consisted of teniposide, cyclophosphamide and total body irradiation (TBI). Graft versus host disease (GVHD) preparative regimen included cyclosporine and a short term of methotrexate. The patients who received Haplo-HSCT combined with UCB infusion and MUD-HSCT were treated with antithymocyte globulin (ATG). Results After the transplantation, one patient in MUD-HSCT group and one in MSD-HSCT group died within 21 days, and other patients were engrafted successfully. The median time of neutrophil engraftment was 13 days (10-18 d), 12 days (9-16 d) and 12 days (9-14 d) in Haplo-HSCT + UCB group, MUD-HSCT group and MSD-HSCT group, respectively;the median time of platelets engraftment was 11 days (9-18 d), 12 days (10-23 d) and 12 days (9-14 d), respectively. There were 10, 3, 3 cases of grade Ⅱ-Ⅳacute GVHD at day 100 in the three groups, respectively, and there were 6, 4, 3 cases of chronic GVHD in the three groups, respectively. The 2-year cumulative incidence of relapse was 40.6%, 66.2% and 26.7%, respectively. The predicted 2-year overall survival rate was 37.9%, 42.9% and 55.4%, respectively. All these data had no significant difference (all P> 0.05). Conclusion The efficacy of Haplo-HSCT combined with UCB infusion is similar to that of MUD-HSCT or MSD-HSCT in treatme

关 键 词：淋巴细胞肿瘤 异基因造血干细胞移植 胎血 

分 类 号：R733[医药卫生—肿瘤]